welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
MDA Releases Duchenne Fact Sheet, Survey Results Pointing to Need for Knowledge of Clinical Trials and Genetic Tests
Citing a persistent need for new treatments and patient support, the Muscular Dystrophy Association (MDA) has updated its Duchenne muscular dystrophy (DMD) fact sheet.
In related news, two top issues identified in a landmark MDA-funded survey of neuromuscular disease families were access to quality care along with a greater knowledge of genetic testing and clinical trials.
The fact sheet is intended for use by DMD families, patients’ teachers, and care providers, and includes an overview of Duchenne as well as its symptoms, treatment choices, essential facts and a terms glossary.
Its release was timed with Duchenne Muscular Dystrophy Awareness Week, Feb. 13–18, a news release said. The three-page guide notes, for example, that Duchenne affects 1 in 5,000 newborn boys, and that, owing to advances in cardiac and respiratory care, their life expectancy is generally increasing.
rareRelated
-
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)This is an open-label, extension study o...
-
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrop...Catabasis Pharmaceuticals, Inc., a clini...
-
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular DystrophyThis is an open-label study to assess th...
-
A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular DystrophyThis is a first-in-human/first-in-patien...
-
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne M...This is a Phase 2 randomized, 2-period, ...
-
Study of Eteplirsen in Young Patients With DMD Amenable to Exon 51 SkippingThis is a multicenter, open-label, dose-...
-
Edasalonexent could reduce functional decline in boys with DMD, MoveDMD phase 2 results suggestResults of the Phase 2 MoveDMD trial sho...
-
Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business UpdateSolid Biosciences Inc. today reported fi...
-
PTC Therapeutics Phase III Duchenne Muscular Dystrophy (DMD) Clinical TrialPTC Therapeutics, Inc. is seeking pa...
-
How Facebook and Twitter could be the next disruptive force in clinical trialsAmber Sapp was browsing the Internet lat...
